NCT03828799 2026-02-27
FOLFIRINOX-R
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
Institut du Cancer de Montpellier - Val d'Aurelle
Bristol-Myers Squibb
Bristol-Myers Squibb
ImmunityBio, Inc.
Sumitomo Pharma America, Inc.
Hoffmann-La Roche
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins